Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817813 | 0.89 | HTR2C (0.49) | HPGDDRD3DRD2DRD4MTNR1A | |
| SCHEMBL7781216 | 0.86 | HPGD (0.52) | HPGDSLC6A4DRD3DRD2DRD4 | |
| SCHEMBL8882719 | 0.86 | HPGD (0.52) | HPGDSLC6A4DRD3DRD4PREP | |
| SCHEMBL7778725 | 0.86 | PLD1 (0.51) | HPGDSLC6A4DRD3 | |
| SCHEMBL7811687 | 0.83 | CCR2 (0.46) | HPGDDRD4 | |
| SCHEMBL7811689 | 0.83 | DRD4 (0.51) | HPGDDRD2DRD4MTNR1AMTNR1B | |
| SCHEMBL8576249 | 0.83 | F10 (0.39) | HPGDDRD3DRD2MTNR1AMTNR1B | |
| SCHEMBL7781808 | 0.78 | HTR2C (0.43) | DRD3DRD2DRD4 | |
| SCHEMBL10720014 | 0.78 | HPGD (0.70) | HPGDSLC6A4DRD3DRD2DRD4 | |
| SCHEMBL7814210 | 0.77 | HTR1A (0.43) | HPGDDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133293-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| EP-0775113-B1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AG (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000030639-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0775113-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004245-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-15 | — | — | WO | disclosed |